BIO from the BAYOU

The episode surfaces a few genuinely non-obvious points - the USDA/FDA split for animal health products, the absence of vaccine hesitancy in livestock due to pure economics, the data infrastructure gap limiting AI application in animal health, and CAR-T cells being tested in dogs as a lower-risk proving ground. However, the density is diluted significantly by a lengthy origin-story segment, personal anecdotes, and high-level statements that never fully develop.

“What people don't know is that animal health products in the U.S., there's two regulatory agencies. The FDA for everything that's a pharmaceutical. And then you have the USDA for everything that has something to do with the immune system.”

“there's no vaccine hesitancy in livestock animals because the farmers know, if I don't vaccinate my pigs, if I don't vaccinate my cattle, I will make less money with them”

The investor anecdote about being told to drop the dog oncology program and the USDA-vs-FDA regulatory philosophy contrast are genuinely fresh angles; the CAR-T-in-dogs observation is a mildly counterintuitive idea. But the broader framing - animal health is underexplored, AMR is a shared threat, vaccines reduce antibiotic use - cycles through familiar public-health talking points without a strong contrarian or first-principles argument.

“it's great until you tell your investors that you want to spend some money to treat dogs. And then your investors tell you, drop it right now. We don't make any money with dogs.”

“In-situ, let's say CAR-T cells in dogs, it's less risky. We can do in-situ vaccinations and things like that. But this is really, I think this is a whole space that we say, oh, you would never try this in humans.”

Dr. Ehrlman is a genuine practitioner - Global Head of Biological Development and Animal Health at Boehringer Ingelheim, with a traceable arc from a startup exit in oncolytic viruses through human pharma to leading BI's entire biologics pipeline across species. He is not a career thought-leader; he has actually done the science and the deals, which shows in specific regulatory and development nuance.

“we had four stars of clinical trials and human pharma with oncolytic viruses and oncolytic cancer vaccines, some of those are still running”

“we also have antibodies. We have the odd stem cell. We have proteins. We have bacteria. We have viruses. And of course, we have a host of hosts.”

The episode offers some concrete anchors - named BI facilities in Athens GA, St. Joseph MO, and Ames IA; the USDA/FDA regulatory split; the one-pivotal-trial pathway; and modality-level detail (mRNA, novel adjuvants, CAR-T). What is almost entirely absent is market-size data, revenue comparisons, trial timelines, clinical outcome metrics, or named partner companies, leaving many claims unverified.

“Before that, I was in St. Joseph, Missouri, where we have also production and development facility. And we have a nice research facility in Ames, Iowa.”

“we just do basically one trial. We do one pivotal clinical trial in a diseased animal”

The host is clearly knowledgeable and asks structurally reasonable questions (regulatory process, tech transfer angle, market trends), but the session is far too cozy - personal anecdotes about her dachshund's acupuncture, her deaf dog, and a skunk-odor neutralizer consume airtime without advancing the conversation, and there are no follow-up challenges or moments of productive disagreement with a guest who could have been pressed much harder.

“my old dachshund has gotten acupuncture for his back before I've gotten acupuncture for my back”

“I'm just going to throw this out there, a hearing drug for dogs. Because yes, I have literally barked up this tree myself”